AR062427A1 - Derivados heteroarilo como inhibidores de citocina - Google Patents

Derivados heteroarilo como inhibidores de citocina

Info

Publication number
AR062427A1
AR062427A1 ARP070103676A ARP070103676A AR062427A1 AR 062427 A1 AR062427 A1 AR 062427A1 AR P070103676 A ARP070103676 A AR P070103676A AR P070103676 A ARP070103676 A AR P070103676A AR 062427 A1 AR062427 A1 AR 062427A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
substituted
independently
unsubstituted
Prior art date
Application number
ARP070103676A
Other languages
English (en)
Inventor
Christopher J Larson
Jay Zhu
Erik Boman
Justin Emst
Montalban Antonio Garrido
Lubomir Sebo
Yazhong Pei
Jan Urban
Zhijun Wang
Christopher Lum
Original Assignee
Kemia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemia Inc filed Critical Kemia Inc
Publication of AR062427A1 publication Critical patent/AR062427A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems

Abstract

La presente proporciona compuestos de bajo peso molecular utiles como inhibidores de citocina, y composiciones del mismo. Se proporcionan además métodos para la preparacion de tales agentes y su uso en prevenir y tratar condiciones mediadas por citocinas. En particular, son utiles como agentes anti-inflamatorios, anti-dolor o anti-cáncer. Reivindicacion 6: Un compuesto de la formula 1, estereoisomeros del mismo, tautomeros del mismo, solvatos del mismo, profármacos del mismo, y sales farmacéuticamente aceptables del mismo; en donde X es CH, N, o NO; Y es CH, N, NO, con la condicion de que X y Y no sean ambos CH o NO; A es F, CI, Br, I, NR2, o un grupo alquilo C1-3 o -O(alquilo C1-3), en donde el grupo alquilo se halogena parcial o completamente de manera opcional; G es un grupo arilo o heteroarilo, en donde G se sustituye por uno o más R1, R2 o R3; Ar es un grupo arilo o heteroarilo de 6 miembros; L1 es -C(O)NH-; L2 es un enlace covalente, grupo (CR'2)s, (CR'2)nO(CR'2)t, (CR'2)nNR(CR'2)t, (CR'2)nC(NOR), (CR'2)nSO2NR(CR'2)t, (CR'2)nC(O)(CR'2)t, O(CR'2)tC(O)(CR'2)n, O(CR'2)sNR(CR'2)n, O(CR'2)nC(O)NR(CR'2)t, O(CR')sNRC(O)(CR'2)n, (CR'2)nC(O)NR(CR'2)t, (CR'2)nC(O)NRNR(CR'2)t, o (CR'2)nNRC(O)O(CR'2)t; Q es un grupo alquilo, cicloalquilo, arilo, heterociclilo, cicloalquilalquilo, aralquilo, o heterociclilalquilo sustituido o no sustituido; cada R1 es independientemente F, CI, Br, I, -NR2, -CN, o un grupo alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, arilo, heterociclilo, o heterociclilalquilo sustituido o no sustituido; cada R2 es independientemente F, CI, Br, I, -CN, -NO2, un grupo alquilo o heterociclilalquilo sustituido o no sustituido, -OR', -C(O)R', -C(O)OR', -C(O)NR'2, C(NR)NR2, -C(NR)NROR, -NR'2, -(CR'2)tNRR', -NRC(O)Rö, -NR'C(O)ORö, -NR'SO2Rö, -NR'C(O)NR'2, -NR'C(S)NR'2, - S(O)mRö, o -SO2NR'2; cada R3 es independientemente un grupo alquilo, alquenilo, o alquinilo sustituido o no sustituido, o un grupo -O(alquilo C1-4), en donde el grupo alquilo C1-4 se halogena parcial o completamente de manera opcional; cada R es independientemente hidrogeno o un grupo alquilo C1-6 sustituido o no sustituido; cada R' es independientemente hidrogeno, o un grupo alquilo, cicloalquilo, cicloalquilalquilo, aralquilo, heterociclilo, o heterociclilalquilo sustituido o no sustituido; cada Rö es independientemente un grupo alquilo, cicloalquilo, arilo, heterociclilo, cicloalquilalquilo, aralquilo o heterociclilalquilo sustituido o no sustituido; cada m es independientemente 0, 1 o 2; n es 0, 1, o 2; s es 1, 2, o 3; y cada t es independientemente 0, 1, o 2; a condicion de que el compuesto no sea 5-(bifenil-4-il)-6-cloro-N-(6-metoxipiridin-3-il)nicotinamida.
ARP070103676A 2006-08-17 2007-08-17 Derivados heteroarilo como inhibidores de citocina AR062427A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83879506P 2006-08-17 2006-08-17
US89147007P 2007-02-23 2007-02-23

Publications (1)

Publication Number Publication Date
AR062427A1 true AR062427A1 (es) 2008-11-05

Family

ID=39082322

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103676A AR062427A1 (es) 2006-08-17 2007-08-17 Derivados heteroarilo como inhibidores de citocina

Country Status (5)

Country Link
AR (1) AR062427A1 (es)
CL (1) CL2007002375A1 (es)
PE (1) PE20080906A1 (es)
TW (1) TW200815422A (es)
WO (1) WO2008021388A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1907382E (pt) 2005-07-26 2015-09-25 Bial Portela & Ca Sa Derivados de nitrocatecol como inibidores de comt
TW201018662A (en) 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
KR101522157B1 (ko) 2007-01-31 2015-05-28 바이알 - 포르텔라 앤드 씨에이 에스에이 Ｃｏｍｔ 억제제의 투약 방법
CN101669030B (zh) 2007-03-08 2016-01-13 小利兰·斯坦福大学托管委员会 线粒体醛脱氢酶2调节剂和其使用方法
EA015952B1 (ru) 2007-05-03 2011-12-30 Пфайзер Лимитед 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
EP2111223A4 (en) 2007-11-01 2012-08-15 Acucela Inc AMIN DERIVATIVE COMPOUNDS FOR THE TREATMENT OF EYE DISEASES AND DRESSES
BRPI0908731A2 (pt) 2008-03-17 2017-05-16 Bial - Portela & C A S A formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-óxi-piridina-3-il)[1,2,4]oxadiazol-5-il]-3-nitrobenzeno-1,2-diol
EA201001847A1 (ru) * 2008-06-11 2011-08-30 Айрм Ллк Соединения и композиции, применяемые для лечения малярии
AR073501A1 (es) 2008-09-08 2010-11-10 Boehringer Ingelheim Int Derivados de pirimido[5,4-d]pirimidina inhibidores de la tirosinoquinasa
WO2010028175A1 (en) 2008-09-08 2010-03-11 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
TW201018670A (en) 2008-09-29 2010-05-16 Boehringer Ingelheim Int New chemical compounds
WO2010062308A1 (en) 2008-10-28 2010-06-03 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
CN102264737A (zh) * 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
CA2740195A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
JP5603883B2 (ja) 2009-02-17 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂ−Ｒａｆキナーゼを阻害するためのピリミドピリミジン誘導体
PT2413912T (pt) 2009-04-01 2019-06-11 Bial Portela & Ca Sa Formulações farmacêuticas compreendendo derivados de nitrocatecol e métodos para as produzir
RU2541571C2 (ru) 2009-04-15 2015-02-20 Эббви Инк. Противовирусные соединения
FR2953519B1 (fr) 2009-12-08 2012-02-10 Commissariat Energie Atomique Nouveaux composes chimiques aptes a complexer au moins un element metallique et complexe de coordination a base de ces composes
US8865703B2 (en) 2010-03-26 2014-10-21 Boehringer Ingelheim International Gmbh Pyridyltriazoles
EP2552905B1 (en) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH B-Raf kinase inhibitors
EP2583965B1 (en) * 2010-07-15 2017-01-25 Takeda Pharmaceutical Company Limited Heterocyclic ring compound
US8410107B2 (en) * 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
EP2791134B1 (en) 2011-12-13 2019-09-25 BIAL - Portela & Cª S.A. Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
RU2015124564A (ru) * 2012-12-10 2017-01-12 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ БЕНЗОЛСУЛЬФОНАМИДА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ RORc
KR20150135332A (ko) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
US9233961B2 (en) 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
WO2014170648A1 (en) 2013-04-19 2014-10-23 Astrazeneca Ab A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
HUE040254T2 (hu) 2013-12-19 2019-02-28 Novartis Ag Protozoa proteaszóma inhibitor [1,2,4]triazolo[1,5-a]pirimidinszármazékok paraziták által okozott betegségek, például leishmaniasis kezelésére
JP6544523B2 (ja) * 2014-01-31 2019-07-17 日産化学株式会社 液状農薬組成物
RU2017120184A (ru) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
CN104926738B (zh) * 2015-06-08 2017-05-24 南京农业大学 一类1,2,3‑***‑4‑酰肼衍生物在制备农用杀菌剂中的应用
EP3394059B1 (en) 2015-12-23 2020-11-25 Chiesi Farmaceutici S.p.A. 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors
BR112018067538A2 (pt) 2016-03-03 2019-02-05 Univ Cornell inibidores de ire1-alfa de pequenas moléculas
JP2019529579A (ja) * 2016-10-03 2019-10-17 シギロン セラピューティクス， インコーポレイテッドＳｉｇｉｌｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 化合物、デバイスおよびその使用
US11571429B2 (en) * 2017-05-23 2023-02-07 Upexmed Co. Ltd. Method and compounds for treating peripheral neuropathy
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN114732910A (zh) 2017-10-05 2022-07-12 弗尔康医疗公司 P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
CN111220737A (zh) * 2018-11-27 2020-06-02 罗欣药业(上海)有限公司 一种分离依折麦布及其光学异构体的方法
JPWO2020175680A1 (es) * 2019-02-28 2020-09-03
CN110095463B (zh) * 2019-03-15 2021-10-22 中国人民解放军陆军军医大学第二附属医院 一种乳糜定性检测的试剂盒
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
CN116761801A (zh) * 2021-03-12 2023-09-15 四川科伦博泰生物医药股份有限公司 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CN115089590B (zh) * 2022-06-13 2023-05-12 同济大学 环戊基***嘧啶类药物作为药物成分在肝炎药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534328A (ja) * 2000-05-25 2003-11-18 メルク フロスト カナダ アンド カンパニー フルオロアルコキシ置換ベンズアミドジクロロピリジニルｎ−オキシドｐｄｅ４阻害剤

Also Published As

Publication number Publication date
CL2007002375A1 (es) 2008-04-04
TW200815422A (en) 2008-04-01
WO2008021388A1 (en) 2008-02-21
PE20080906A1 (es) 2008-07-05

Similar Documents

Publication Publication Date Title
AR062427A1 (es) Derivados heteroarilo como inhibidores de citocina
AR116993A2 (es) Compuestos heterociclos bicíclicos y sus usos en terapia
BRPI0818193B8 (pt) composto, composição farmacêutica, e, uso de um composto
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR062526A1 (es) DERIVADOS DE 4-(3-METILMORFOLIN-4-IL)PIRIMIDINA Y MORFOLIN-4-IL-PIRIMIDINA COMO INHIBIDORES DE MTOR QUINASA Y PI3K, UNA COMPOSICIoN FARMACEUTICA QUE LOS COMPRENDE Y EL USO DE LOS MISMOS EN LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE DIVERSOS TIPOS DE CANCER.
AR082109A1 (es) Derivados de bipiridilo
AR081848A1 (es) Inhibidores de la proteina ns5a del vhc
BRPI0409117A (pt) compostos n-heterocìclios condensados e seu uso como antagonistas do receptor de crf
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
RS54288B1 (en) SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS
BRPI0508321A (pt) hidróxi-6-heteroarilfenantridinas e seu uso como inibidores de pde4
AR077130A1 (es) Inhibidores de la replicacion de los virus de influenza
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
RU2011108024A (ru) 3-азабицикло(3.1.0) гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов
AR071739A1 (es) Inhibidores de transcriptasa reversa
AR076550A1 (es) Inhibidores de la janus tirosina kinasa (jak)
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
AR083339A1 (es) Compuestos de quinazolina como bloqueadores de los canales de sodio
ECSP099335A (es) Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos
EA201290520A1 (ru) Производные дифенилпиразолопиридинов, их получение и применение в качестве модуляторов нуклеарного рецептора not
AR102213A1 (es) Inhibidores de la biosíntesis de sulfato de heparano para el tratamiento de enfermedades
AR076008A1 (es) Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos.
RU2014121205A (ru) Производные азолов
AR072622A1 (es) Derivados de imidazo[2,1-b][1,3,4]tiadiazol, composiciones farmaceuticas que los comprenden, metodo para prepararlos, y uso de los mismos para el tratamiento de tumores y otras enfermedades inducidas por quinasas

Legal Events

Date Code Title Description
FB Suspension of granting procedure